Ascendis Pharma A/S ASND

On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does […]

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

Ascendis Pharma (ASND) share selloff on Tuesday after the termination of its collaboration agreement

Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD

Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program). Purchases under the planned Share Repurchase Program may be made from time to time, in such amounts as management deems appropriate, through a variety of methods, which may include open market purchases, privately negotiated transactions, b

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis Pharma A/S (NASDAQ:ASND) to resolve a global patent dispute over Ascendis’s achondroplasia drug Yuviwel. The settlement resolves litigation currently pending in numerous jurisdictions, including a Section 337 investigation by the US International […]

Ascendis Pharma A/S (NASDAQ:ASND) on Wednesday announced Week 52 data from the open-label sentinel cohort of its reACHin trial. The data showed that once-weekly TransCon CNP (navepegritide) provided stabilization or improvement in foramen magnum stenosis alongside linear growth benefits in infants with achondroplasia aged 0 to under 2 years. Read Also: Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes Growth And Cranio-Cervical Health Treatment with TransCon CN

– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement in ACH-specific supine length Z-score of +0.42 from baseline through Week 52 – Treatment with TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period COPENHAGEN, Denmark, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Phar

Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan.Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, G

COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time in New York, New York. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast repl

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondrop

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has converted a global patent dispute with Ascendis Pharma A/S (NASDAQ:ASND) into a royalty-bearing license for Yuviwel, a once-weekly treatment approved to increase linear growth in children aged 2 years and older with achondroplasia and open epiphyses. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will receive royalties equal to 20% of U.S. Yuviwel net […]